| Dr. Mel Featured on Walgreen's health segment |
|
|
| Written by Jeff Bailey | |
| Wednesday, 17 October 2007 | |
|
You may have missed it this past weekend, but Dr. Mel was featured in a health segment produced for Walgreen's drug stores that aired on the Lifetime cable network this past weekend. ![]() Dr. Mel on Walgreens Health segment The segment recaps the treatments Mel has received since he was first diagnosed eleven years ago, including drug trials at the Dana-Farber Cancer Center in Boston. "If it weren't for clinical trials, I wouldn't be here talking with you," he said on the segment.You can catch the segment when it re-airs December 2nd, or you can see it right now on the Walgreens site. |
| < Prev | Next > |
|---|
Multiple Myeloma News Update
-
Research forum Sept. 16 to focus on multiple myeloma
UConn Advance, CT - 2 hours ago
... research forum focusing on issues related to contemporary clinical and investigative approaches to multiple myeloma will take place on Tuesday, Sept. ... -

Network MédicaBiogen Idec and Elan Corp Announce Start of Trials with Tysabri as ...
Network Médica, Argentina - 2 hours ago
The treatments for multiple myeloma are led by biotech Celgene, with several drugs on the market: Revlimid, with sales for $ 613 million dollars in the ... -

Network MédicaBiogen to test Tysabri as a cancer treatment
Bizjournals.com, NC - 4 hours ago
Eligible candidates must have multiple myeloma and have failed with previous treatments. Biogen Idec makes Tysabri at a manufacturing plant in Research ...
Biogen’s battered MS drug in cancer treatment trials Mass High Tech
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI® in ... elEconomista.es
Tysabri clinical study underway Hays Pharma
Pharma Times (subscription)all 37 news articles -
Bortezomib plus melphalan-prednisone improved response rate in ...
HemOncToday, NJ - 9 hours ago
Melphalan and prednisone plus bortezomib may improve time to progression in patients with newly diagnosed multiple myeloma. According to researchers from ... -
Elan, Biogen Idec commence first clinical trial of Tysabri in ...
RTT News, NY - 15 hours ago
Patients with eighteen years and above suffering from relapsed or refractory multiple myeloma and those who failed or cannot tolerate therapy with ... -
Elan, Biogen launch Tysabri trial in oncology
Reuters - 16 hours ago
The first dose was administered on Thursday, they said. Multiple myeloma is a cancer of the plasma cell. (Reporting by Jonathan Saul; Editing by Quentin Bryar) -
Human Genome Sciences reports initial results from Phase II ...
Pharmaceutical Business Review - 21 hours ago
By Staff Writer The initial data from the multiple myeloma study show that HGS-ETR1 was well tolerated and suggest that disease response was comparable for ... -
Human Genome Sciences Reports Initial Results Of Randomized Phase ...
Medical News Today (press release), UK - Sep 4, 2008
The initial data from the multiple myeloma study show that HGS-ETR1 was well tolerated and suggest that disease response was comparable for this combination ...













